Volrustomig: all 23 studies that test it
Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck CancerRecruitingNCT07065630Phase 2
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsRecruitingNCT06535607Phase 2
- A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent ChemoradiotherapyRecruitingNCT06129864Phase 3
- Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)RecruitingNCT06079671Phase 3
- MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.Not yet recruitingNCT05888857Phase 2
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT05702229Phase 2
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2
- WIRE - Novel Treatments in Renal Cell CancerRecruitingNCT03741426Phase 2
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCActive, not recruitingNCT07000149Phase 1
- A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)Active, not recruitingNCT06943833Phase 2
- A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerActive, not recruitingNCT06792695Phase 2
- Volrustomig Priming Regimens Exploratory Phase II Platform StudyActive, not recruitingNCT06448754Phase 2
- PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompletedNCT06366451Early Phase 1
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaActive, not recruitingNCT06097728Phase 3
- A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05984277Phase 3
- Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic SarcomaCompletedNCT05821231Phase 1
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
- MEDI5752 in Japanese Patients With Advanced Solid Tumors.CompletedNCT05685472Phase 1
- Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingNCT04541108Early Phase 1
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaActive, not recruitingNCT04522323Phase 1
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingNCT04379596Phase 2
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingNCT03819465Phase 1
- A Study to Evaluate MEDI5752 in Subjects With Advanced Solid TumorsActive, not recruitingNCT03530397Phase 1